BIOGEN HIRLULOG LOWER INCIDENCE OF BLEEDING COMPLICATIONS v. HEPARIN IS DEEMED INSUFFICIENT CLINICAL RESULT; FIRM REDEPLOYING RESOURCES TO BETA INTERFERON
A lower incidence of bleeding complications for Biogen's Hirulog compared to heparin following angioplasty was not enough of a clinical result to convince Biogen to continue developing the synthetic leech protein derivative hirudin. Cambridge, Mass.-based Biogen announced Oct. 31 that it is abandoning Hirulog following a preliminary review of Phase III trial results.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth